Clinical Trials
15 trialsNCT07624487 2026-06-03
A Phase II Study of Aumolertinib Combined With Phased Chemotherapy for EGFR L858R Lung Adenocarcinoma
Taipei Medical University Hospital
Phase 2 Not yet recruiting
NCT05198830 2026-05-27
Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT00334815 2026-05-26
Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT02186847 2026-05-22
Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer
NRG Oncology
Phase 2 Completed
NCT05456256 2026-05-04
HARMONIC
Lantern Pharma Inc.
Phase 2 Recruiting
NCT05528458 2026-04-28
Osimertinib to Suppress the Progression of Remaining GGN for EGFR Mutation-positive Stage IB-IIIA Lung Adenocarcinoma
Samsung Medical Center
Phase 2 Recruiting
NCT03110978 2026-04-16
Stereotactic Body Radiation Therapy With or Without Nivolumab in Treating Patients With Stage I-IIA or Recurrent Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT06495125 2026-04-06
Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer
Emory University
Phase 2 Recruiting
NCT07482605 2026-03-20
Furmonertinib Plus Radiotherapy for EGFR+ NSCLC With Pleural Effusion
Jiangmen Central Hospital
Phase 2 Not yet recruiting
NCT07416058 2026-02-17
PHOENIX
Guangdong Association of Clinical Trials
Phase 2 Not yet recruiting
NCT04625647 2025-12-05
Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
SWOG Cancer Research Network
Phase 2 Active not recruiting
NCT04557449 2025-10-01
CDK4i
Pfizer
Phase 2 Active not recruiting
NCT03184571 2025-09-25
Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
BerGenBio ASA
Phase 2 Completed
NCT04105270 2025-09-11
RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial
Masonic Cancer Center, University of Minnesota
Phase 2 Recruiting
NCT04533451 2025-06-13
Testing the Effects of MK-3475 (Pembrolizumab) With or Without the Usual Chemotherapy Treatment for Patients 70 Years of Age and Older With Advanced Non-small Cell Lung Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Active not recruiting